CG Oncology
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
Domain
cgoncology.com
Country
United StatesIndustry
BiotechnologyEmployees
101-250
Last Funding
$238.0M
Founded
2009
Tech Stack (17 technologies)
Frequently Asked Questions
What technologies does CG Oncology use?+
CG Oncology uses 17 technologies including Bootstrap, Divi, Google Analytics.
What industry is CG Oncology in?+
CG Oncology operates in the Biotechnology industry.
Where is CG Oncology based?+
CG Oncology is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026